Immuneering to Present at the Leerink Global Healthcare Conference

Rhea-AI Summary

Immuneering (Nasdaq: IMRX) will present at the Leerink Global Healthcare Conference in Miami, March 9-11, 2026. CEO Ben Zeskind will deliver a fireside chat and hold 1x1 investor meetings on March 9, 2026, 3:40–4:10 pm ET.

The presentation will be webcast live and archived in the company's Investor Relations Events & Presentations section.

News Market Reaction – IMRX

-1.00%

2 alerts

-1.00% Session close to close

$336.40M Market Cap

0.7x Rel. Volume

In the Mar 3 session, IMRX declined 1.00%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights continued investor outreach, with Immuneering presenting its pipeline a...

Analysis

This announcement highlights continued investor outreach, with Immuneering presenting its pipeline and strategy at the Leerink Global Healthcare Conference from March 9–11, 2026. It follows recent clinical and regulatory milestones and adds another webcasted forum for management to update investors. With an existing $300,000,000 shelf and prior use of equity distribution, investors may watch for any capital‑raising steps, alongside progress of the MAPKeeper 301 Phase 3 program and further survival data updates.

Key Figures

Conference dates: March 9–11, 2026 Presentation time: 3:40–4:10 pm ET Shelf registration: $300,000,000 +1 more

4 metrics

Conference dates March 9–11, 2026 Leerink Global Healthcare Conference in Miami, Florida

Presentation time 3:40–4:10 pm ET Immuneering fireside chat on March 9, 2026

Shelf registration $300,000,000 Total securities registered under Form S-3 shelf

ATM capacity $100,000,000 Potential Class A common stock sales via Piper Sandler under shelf

Historical Context

5 past events · Latest: Feb 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 18	Investor conference	Positive	+4.4%	Oppenheimer healthcare conference presentation with webcast and 1x1 investor meetings.
Jan 07	Clinical data update	Positive	-43.2%	Updated Phase 2a pancreatic cancer data showing strong 12-month survival metrics.
Jan 07	Clinical data preview	Positive	+8.1%	Announcement of upcoming webcast to present 12‑month overall survival results.
Dec 17	Phase 3 planning	Positive	+3.1%	Secured FDA and EMA alignment for global Phase 3 MAPKeeper 301 trial design.
Dec 16	Index inclusion	Positive	-0.7%	Expected addition to the Nasdaq Biotechnology Index prior to December 22, 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past conference and index-related news often saw modest moves, while major clinical data sometimes produced sharp, even negative, reactions.

Recent Company History

Over the last few months, Immuneering has transitioned from index recognition to pivotal clinical planning. In December 2025, the company advanced its Phase 3 MAPKeeper 301 trial design with FDA and EMA alignment and noted cash funding into 2029. Subsequent updates included strong Phase 2a pancreatic cancer survival data on January 7, 2026 and multiple investor conference appearances, such as Oppenheimer on February 25–26, 2026. Today’s Leerink conference participation continues this pattern of investor outreach and pipeline visibility.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Leerink Global Healthcare Conference, taking place in Miami, Florida, from March 9-11, 2026. Ben Zeskind, Chief Executive Officer, will discuss the company’s pipeline, platform, and business strategy.

Format: Fireside Chat and 1x1 Investor Meetings

Date/Time: Monday, March 9, 2026, from 3:40 – 4:10 pm ET

The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering

Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. The company expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and early-stage programs. For more information, please visit www.immuneering.com.

Investor Contact:
Courtney Dugan
Cdugan@immuneering.com

Media Contact:
Gina Nugent
Gina.nugent.external@immuneering.com

FAQ

When will Immuneering (IMRX) present at the Leerink Global Healthcare Conference?

Immuneering will present on March 9, 2026, from 3:40–4:10 pm ET. According to Immuneering, CEO Ben Zeskind will lead a fireside chat and hold 1x1 investor meetings during the conference in Miami.

How can investors watch Immuneering's (IMRX) Leerink conference presentation?

Investors can view a live webcast of the presentation and later watch the archived replay. According to Immuneering, the webcast and archive will be posted in the Investor Relations Events & Presentations section of the company's website.

Who will represent Immuneering (IMRX) at the Leerink Global Healthcare Conference?

Ben Zeskind, Immuneering's Chief Executive Officer, will represent the company in the fireside chat and 1x1 meetings. According to Immuneering, he will discuss the company's pipeline, platform, and business strategy.

What topics will Immuneering (IMRX) cover during the March 9, 2026 presentation?

The presentation will cover Immuneering's pipeline, platform, and business strategy. According to Immuneering, CEO Ben Zeskind will address development programs and the company's clinical oncology focus during the fireside chat.

Where and when is the Leerink Global Healthcare Conference that features Immuneering (IMRX)?

The conference takes place in Miami, Florida, from March 9–11, 2026. According to Immuneering, the company's presentation is scheduled for March 9 with both a fireside chat and 1x1 investor meetings.